PCM
VRCA icon

Prelude Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Prelude Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,009
Closed -$233K – 2076
2019
Q2 		$233K Sell
2,009
-620
-24% -$58.2K 0.01% 687
2019
Q1 		$284K Buy
+2,629
New +$303K 0.02% 614
2018
Q4 		– Sell
-3,481
Closed -$566K – 2189
2018
Q3 		$566K Buy
3,481
+481
+16% +$82.2K 0.03% 494
2018
Q2 		$592K Buy
+3,000
New +$588K 0.04% 481

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Prelude Capital Management's VRCA Position: Q3 2019 in Review

Prelude Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q3 2019, closing a stake of 2,009 shares — an estimated $233K sold.

Prelude Capital Management first reported a position in VRCA in Q2 2018 and held it in 4 quarters. The position peaked at $592K in Q2 2018. 42 funds tracked by Wall St. Rank hold VRCA as of Q3 2019.

  • Prelude Capital Management reported no remaining Verrica Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Prelude Capital Management sold 2,009 Verrica Pharmaceuticals shares in Q3 2019, an estimated $233K.
  • Prelude Capital Management first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Prelude Capital Management's Verrica Pharmaceuticals position peaked at $592K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2019.

Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.